NBTX | Nanobiotix S.A. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.57 - 4.11
52 Week Range	3.57 - 8.96
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	14,656
Average Volume	8,711
Shares Outstanding	47,111,182
Market Cap	191,671,844
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-11

Valuation
Profitability
Growth
Health
P/E Ratio	-5.22
Forward P/E Ratio	N/A
EPS	-0.78
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	110
Country	France
Website	NBTX

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

NBTX's peers: ZURA, ANNX, ICVX, INAB, WVE, IMMX, CNSP, HEPA, FRLN, AVRO, CGTX, TFFP, TCRX, CUE, DRMA, CYTO, ENVB, PALI, ZVSA, EFTR, VECT

*Chart delayed

Analyzing fundamentals for NBTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NBTX Fundamentals page.

Watching at NBTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NBTX Technicals page.